<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">Waldenstr√∂m macroglobulinaemia</z:e> (WM) is a disease the incidence of which is approximately 10 times lower than that of <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The incidence of WM is reported to be respectively 0.34 per 100,000 men and 0.7 per 100,000 women </plain></SENT>
<SENT sid="2" pm="."><plain>It is one of the less aggressive <z:e sem="disease" ids="C0024314" disease_type="Neoplastic Process" abbrv="">lymphoproliferative diseases</z:e> in which therapy is indicated only when the disease symptoms start to manifest </plain></SENT>
<SENT sid="3" pm="."><plain>We present a retrospective analysis of patients with the symptomatic form of WM who were treated with chemotherapy in our centre over the last 9 years, i.e. 19 WM patients (of which 7 women and 12 men) </plain></SENT>
<SENT sid="4" pm="."><plain>The median age upon diagnosis of the symptomatic form of WM and start of treatment was 59 (51-78) years </plain></SENT>
<SENT sid="5" pm="."><plain>The median follow up for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 31 (7-121) months </plain></SENT>
<SENT sid="6" pm="."><plain>The most frequent indication for WM treatment was <z:hpo ids='HP_0001903'>anaemia</z:hpo> in 57% (11/19), <z:e sem="disease" ids="C0040034" disease_type="Disease or Syndrome" abbrv="">thrombocytopaenia</z:e> in 21% (4/19), plasma hyperviscosity in 42% (8/19), symptomatic <z:hpo ids='HP_0002716'>lymphadenopathy</z:hpo> in 15% (3/19), and pathologic <z:hpo ids='HP_0002797'>osteolysis</z:hpo> in 15% (3/19) ofcases, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Decrease in immunoglobulin concentration under the lower physiological limit is not referred to as a characteristic sign of WM, yet it was recorded in 7 out of 19 patients in our patient group and continued after chemotherapy, with the affected patients suffering from <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in remission more often than those with physiological values of immunoglobulins </plain></SENT>
<SENT sid="8" pm="."><plain>36% (7/19) patients were treated with R-FC (rituximab + fludarabine + <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>) therapy, 15% (3/19) with FC therapy, 15% (3/19) with R-CHOP concluded by high-dose chemotherapy with autologous transplantation in 1 case, and 5% (1/19) with CHOP therapy </plain></SENT>
<SENT sid="9" pm="."><plain>VAD (vancristine, ariamycine and <z:chebi fb="0" ids="41879">dexamethasone</z:chebi>) therapy was used in 10% (2/19) of patients and 10% (2/19) of patients were treated with oral <z:chebi fb="5" ids="28830">chlorambucil</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>The first line of treatment achieved complete remission (CR) in 15% cases (3/15) </plain></SENT>
<SENT sid="11" pm="."><plain>Two patients who achieved CR were treated with R-FC, and one patient with VAD </plain></SENT>
<SENT sid="12" pm="."><plain>Partial remission (PR) was achieved by 63% of patients (12/19) </plain></SENT>
<SENT sid="13" pm="."><plain>Minor response (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) was achieved by 10% (2/19), and stable disease (SD) was recorded in 10% of patients (2/19) after initial treatment </plain></SENT>
<SENT sid="14" pm="."><plain>The first relaps of the disease was recorded in 5 patients (2 of whom had PR and 3 MR) who achieved remission after additional lines of therapy </plain></SENT>
<SENT sid="15" pm="."><plain>Thirteen patients are in the first PR </plain></SENT>
<SENT sid="16" pm="."><plain>With a follow up median of 31 months (7-121), only 2 patients died from other than the underlying disease </plain></SENT>
<SENT sid="17" pm="."><plain>Additional malignant disease was diagnosed in 3 patients: 1 colon <z:mp ids='MP_0002038'>carcinoma</z:mp>, 1 <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and 1 <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="18" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three received fludarabine and cyclophopsphamide as initial therapy </plain></SENT>
<SENT sid="19" pm="."><plain>Of the three patients only the patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> has survived and is now without any evidence of the presence of WM, i.e. in complete remission at 41 months after the start of therapy </plain></SENT>
<SENT sid="20" pm="."><plain>High-dose chemotherapy with autologous transplantation was used in 2 cases, once as part of initial therapy and once as part of the therapy for the first relaps resistant to R-CHOP chemotherapy </plain></SENT>
<SENT sid="21" pm="."><plain>It is not possible to determine the median of the first remission or the median of total survival due to the short follow up interval </plain></SENT>
</text></document>